Claims
- 1. A medium of cell culture reagents, for the maintenance and growth of a pluripotent and/or germ line competent mammalian embryonic (ES) stem cell line, which medium is conditioned by a fibroblast cell clone that produces leukemia inhibitory factor.
- 2. The medium of claim 1, wherein the LIF producing fibroblast cell clone further comprises immortalized rabbit fibroblasts, and further comprises an animal serum or an animal serum replacement.
- 3. The medium of claim 1, wherein the cell culture reagents are selected from the group consisting of inorganic salts, amino acids, vitamins and sugars.
- 4. The medium of claim 2, wherein the serum is a fetal animal serum.
- 5. The medium of claim 2, wherein the serum is a newborn animal serum.
- 6. The medium of claim 1, comprising reagents selected from the group consisting of Phosphate Buffered Saline (PBS); Dulbecco's Modified Eagle Media (D-MEM); Iscove's Modified Media; Dulbecco's Media; McCoy's SA Media; Minimum Essential Media Eagle (MEM); RPMI Media 1640; Medium 199; MCDB Medium; RPMI; Glasgow Minimum Essential Media (GMEM); DMEM/F-12 Media; Hams F-10 Nutrient Mixture; Lebovitz's L-15 Media; CMRL Media; BGJb Medium; Basal Medium Eagle (BME); Brinster's BMOC-3 Medium; Williams Media E; and McCoy's Media.
- 7. The medium of claim 4, wherein the fetal animal serum is fetal bovine serum (FBS).
- 8. The medium of claim 7, wherein the fetal bovine serum is treated by a treatment selected from the group of dialysis, gamma irradiation or heat inactivation.
- 9. The medium of claim 1, further comprising a reducing agent.
- 10. The medium of claim 9, wherein the reducing agent is selected from the group consisting of 2-mercaptoethanol and microhydrin.
- 11. The medium of claim 1, further comprising an antibiotic.
- 12. The medium of claim 11, wherein the antibiotic is selected from the group consisting of penicillin, streptomycin and gentamycin.
- 13. The medium of claim 1, further comprising L-glutamine.
- 14. The medium of claim 1, further comprising EGTA.
- 15. The medium of claim 1, further comprising albumin.
- 16. The medium of claim 4, wherein the serum is derived from an animal selected from the group consisting of sheep, pigs, chickens and horses.
- 17. The composition of claim 16, wherein the immortalized fibroblasts have been transfected, transformed or infected by a vector overexpressing a LIF gene.
- 18. The composition of claim 17, wherein the LIF gene is a rabbit LIF gene.
- 19. The composition of claim 18, wherein the fibroblast cell line used for conditioning is the Rab9 #19 cell line, which has been deposited with the Belgian Coordinated Collection of Microorganisms, under accession number LMBP 5479 CB.
- 20. A process of culturing mammalian ES stem cells to obtain pluripotent and/or germ line competent ES cells, wherein the culturing of the mammalian ES stem cells is at least partially performed in a composition as claimed in claim 1.
- 21. The process of claim 20, comprising the steps of:
a) culturing cells of blastocyst stage embryos; b) culturing isolated inner mass cells; and c) passaging the inner mass cells periodically in a composition as claimed in claim 1.
- 22. The process of claim 21, wherein the inner mass cells are periodically passaged for at least eight times.
- 23. The process of claim 20, further comprising the step of producing transgenic animals.
- 24. Embryonic stem (ES) cell line with germ line transmission capability.
- 25. The cell line according to claim 20, which has germ line transmission capability after 11 or more passages.
- 26. The cell line of claim 24, obtainable by the process of claim 20.
- 27. The cell line of claim 24, wherein the cell line is a murine cell line.
- 28. The cell line of claim 27, wherein the cell line has been derived from cells or tissues with 129/SvEv; C57BL/6N; C57BL/6J-HPRT; BALB/c; CBA/CaOla; 129/SvJ; DBA/2n; DBA/1 Ola; C3H/HeN; C57B1; 6Jol1; FVB; or Swiss Webster genetic backgrounds.
- 29. The cell line of claim 28, which has a germ line transmission capability after 11 or more passages.
- 30. The cell line of claim 29, wherein the cell line is cultured in a composition as claimed in claim 1 supplemented with cytokines and growth factors.
- 31. Embryonic stem (ES) cell line of claim 24, characterized by three-dimensional colony formation, positive staining for alkaline phosphatase; and negative staining for cytokeratin 18 and virnentin after more than 10 passages.
- 32. Embryonic stem (ES) cell line of claim 24, for use in the generation of chimeric or ES cell derived animals.
- 33. Embryonic stem (ES) cell line of claim 24, alteration by homologous or non-homologous recombination.
- 34. Embryonic stem (ES) cell line of claim 24, for use in the generation of animals with gene alteration via germ line transmission.
- 35. The method of using the ES cell line of claim 24, for generation of chimeric animals.
- 36. The method of using the ES cell line of claim 35, for the generation of chimeric animals following blastocyst injection into recipient blastocysts or embryo aggregation or nuclear transfer.
- 37. The method of differentiating the ES cell line of claim 24, for the study or isolation of (novel) genes.
- 38. The method of using the ES cell line of claim 24, for the expression or overexpression of genes.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This is a continuation-in-part application of U.S. patent application Ser. No. 09/894,913, filed Jun. 28, 2001, which is a continuation-in-part of U.S. patent application Ser. No. 09/628,883, filed Jul. 31, 2000, which is a continuation-in-part application of U.S. patent application Ser. No. 08/810,945, filed Feb. 27, 1997, now U.S. Pat. No. 6,103,523, issued Aug. 14, 2000, and which is incorporated herein by reference, as combined with U.S. Provisional Patent Application Serial No. 60/214,859, filed on Jun. 28, 2000, which is also incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60214859 |
Jun 2000 |
US |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
09894913 |
Jun 2001 |
US |
Child |
10038279 |
Jan 2002 |
US |
Parent |
09628883 |
Jul 2000 |
US |
Child |
09894913 |
Jun 2001 |
US |
Parent |
08810945 |
Feb 1997 |
US |
Child |
09628883 |
Jul 2000 |
US |